China News Service, Hunan News, January 5 (Li Songjun) In order to help cope with the impact of the Novel Coronavirus virus mutation on the prevention and control of the global epidemic, Sansure Biotech immediately organized a scientific and technological research team to develop a rapid Novel Coronavirus virus identification test kit , Has successfully developed nucleic acid detection reagents for identifying B.1.1.7 Novel Coronavirus virus strains.
The reagent selects the main mutation sites in the S gene, detects the mutation site N501Y that causes enhanced affinity, and the deletion mutation site HV69-70del, which causes the virus to escape human immunity, for identification testing.
This reagent can distinguish between new mutant strains B.1.1.7 and non-mutant strains within 1 hour. At the same time, the reagent can be used with Sansure Biotech’s rapid nucleic acid detection platform, or with Sansure Biotech’s automatic and semi-automatic nucleic acid extraction The platform performs high-throughput identification testing.
In addition, the Novel Coronavirus virus nucleic acid detection kits that Sunshine Bio has previously obtained various authoritative registrations and certifications at home and abroad, target the Novel Coronavirus virus (SARS-CoV-2) ORF1ab gene and the specific conservative sequence encoding the nucleocapsid protein N gene. Region, the design of dual target genes was carried out. Compared with the list of genomic mutations contained in the mutant strain B.1.1.7, no mutations have fallen in the target area designed by the kit. Through professional bioinformatics analysis, the Novel Coronavirus virus nucleic acid detection kit that has been on the market by Sansure Biotech will cover B. 1.1.7 Detection of mutant strains.
Sansure Biotech-Covid-19 Mutant B.1.1.7 identification test kit was successfully developed, which further enriched the company’s Covid-19 detection product line. At present, the company has established the coverage of “Novel Coronavirus Nucleic Acid Test + Novel Coronavirus Antigen Test + Novel Coronavirus POCT Rapid Test + Novel Coronavirus ry/A/B Triple Test + Seven Respiratory Bacteria Test + Six Respiratory Virus Test + Novel Coronavirus Mutant B.1.1.7 The full-scene overall solution of “differential detection” has fully assisted the prevention and control of global Covid-19 epidemic and influenza and other respiratory diseases. The company’s Covid-19 detection products have served more than 150 countries and regions around the world.